Gilead Sciences Live Stock Price Today, Share Analysis and Chart

Name: Gilead Sciences, Inc.: Is Infosys Ltd. worth buying?
Item: Gilead Sciences, Inc.
Rating: 2.25220825
Author: Trendlyne DVM scores

Turnaround Potential

about

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Soval...

146.00 -2.56 (-1.72%)

56.37% Gain from 52W Low

5.5M

XNAS Volume

XNAS 11 Mar, 2026 5:30 PM (EDT)

Dividend

Gilead Sciences has an upcoming dividend of $0.82 per share due on 13 Mar 2026 See details

Low Financial Strength

33.3 / 100

Affordable Valuation

53.0 / 100

Technically Moderately Bullish

60.5 / 100

Turnaround Potential These stocks have weak financials, buying interest and affordable valuations. Investors should exercise caution View Similar Embed DVM

157

1Yr Price target upside is 7%

27 analysts

Gilead Sciences Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Gilead Sciences Live Stock Price Today, Share Analysis and Chart

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Soval...

56.37% Gain from 52W Low

SWOT Analysis

Gilead Sciences Live Price Chart